BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 15557950)

  • 1. Cost-effectiveness of photodynamic therapy for high-grade dysplasia in Barrett's esophagus.
    Vij R; Triadafilopoulos G; Owens DK; Kunz P; Sanders GD
    Gastrointest Endosc; 2004 Nov; 60(5):739-56. PubMed ID: 15557950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of photodynamic therapy for treatment of Barrett's esophagus with high grade dysplasia.
    Hur C; Nishioka NS; Gazelle GS
    Dig Dis Sci; 2003 Jul; 48(7):1273-83. PubMed ID: 12870783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis.
    Shaheen NJ; Inadomi JM; Overholt BF; Sharma P
    Gut; 2004 Dec; 53(12):1736-44. PubMed ID: 15542506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A guide for surveillance of patients with Barrett's esophagus.
    Provenzale D; Kemp JA; Arora S; Wong JB
    Am J Gastroenterol; 1994 May; 89(5):670-80. PubMed ID: 8172136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness model of endoscopic screening and surveillance in patients with gastroesophageal reflux disease.
    Gerson LB; Groeneveld PW; Triadafilopoulos G
    Clin Gastroenterol Hepatol; 2004 Oct; 2(10):868-79. PubMed ID: 15476150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Photodynamic therapy for Barrett's esophagus with high-grade dysplasia: a cost-effectiveness analysis.
    Comay D; Blackhouse G; Goeree R; Armstrong D; Marshall JK
    Can J Gastroenterol; 2007 Apr; 21(4):217-22. PubMed ID: 17431509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk.
    Provenzale D; Schmitt C; Wong JB
    Am J Gastroenterol; 1999 Aug; 94(8):2043-53. PubMed ID: 10445526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness, safety, and cost-effectiveness of photodynamic therapy in Barrett's esophagus: a systematic review.
    Sánchez A; Reza M; Blasco JA; Callejo D
    Dis Esophagus; 2010 Nov; 23(8):633-40. PubMed ID: 20545970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost effectiveness of radiofrequency ablation for Barrett's esophagus.
    Hur C; Choi SE; Rubenstein JH; Kong CY; Nishioka NS; Provenzale DT; Inadomi JM
    Gastroenterology; 2012 Sep; 143(3):567-575. PubMed ID: 22626608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An economic analysis of endoscopic ablative therapy for management of nondysplastic Barrett's esophagus.
    Das A; Wells C; Kim HJ; Fleischer DE; Crowell MD; Sharma VK
    Endoscopy; 2009 May; 41(5):400-8. PubMed ID: 19418393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resection for Barrett's mucosa with high-grade dysplasia: implications for prophylactic photodynamic therapy.
    Ferguson MK; Naunheim KS
    J Thorac Cardiovasc Surg; 1997 Nov; 114(5):824-9. PubMed ID: 9375613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical experience of patients undergoing photodynamic therapy for Barrett's dysplasia or cancer.
    Wolfsen HC; Hemminger LL; Wallace MB; Devault KR
    Aliment Pharmacol Ther; 2004 Nov; 20(10):1125-31. PubMed ID: 15569115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Barrett's esophagus with high-grade dysplasia.
    McAllaster JD; Buckles D; Al-Kasspooles M
    Expert Rev Anticancer Ther; 2009 Mar; 9(3):303-16. PubMed ID: 19275509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cost-utility analysis of ablative therapy for Barrett's esophagus.
    Inadomi JM; Somsouk M; Madanick RD; Thomas JP; Shaheen NJ
    Gastroenterology; 2009 Jun; 136(7):2101-2114.e1-6. PubMed ID: 19272389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Barrett's oesophagus: a review of costs of the illness.
    Arguedas MR; Eloubeidi MA
    Pharmacoeconomics; 2001; 19(10):1003-11. PubMed ID: 11735670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endoscopic versus surgical therapy for early cancer in Barrett's esophagus: a decision analysis.
    Pohl H; Sonnenberg A; Strobel S; Eckardt A; Rösch T
    Gastrointest Endosc; 2009 Oct; 70(4):623-31. PubMed ID: 19394011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surveillance in patients with long-segment Barrett's oesophagus: a cost-effectiveness analysis.
    Kastelein F; van Olphen S; Steyerberg EW; Sikkema M; Spaander MC; Looman CW; Kuipers EJ; Siersema PD; Bruno MJ; de Bekker-Grob EW;
    Gut; 2015 Jun; 64(6):864-71. PubMed ID: 25037191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of endoscopic eradication therapy for treatment of high-grade dysplasia in Barrett's esophagus.
    Filby A; Taylor M; Lipman G; Lovat L; Haidry R
    J Comp Eff Res; 2017 Jul; 6(5):425-436. PubMed ID: 28541099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A UK-based cost-utility analysis of radiofrequency ablation or oesophagectomy for the management of high-grade dysplasia in Barrett's oesophagus.
    Boger PC; Turner D; Roderick P; Patel P
    Aliment Pharmacol Ther; 2010 Dec; 32(11-12):1332-42. PubMed ID: 21050235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient preferences for the management of high-grade dysplasia in Barrett's esophagus.
    Hur C; Wittenberg E; Nishioka NS; Gazelle GS
    Dig Dis Sci; 2005 Jan; 50(1):116-25. PubMed ID: 15712648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.